The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | Promising treatments in CTCL
With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu, MD, from, Sidney Kimmel Cancer Center, Philadelphia, PA, explores the many new drugs that are currently being trialed. Dr Porcu discusses monoclocnal antibody IPH4102, which has shown promising results in Phase I trials as well as oligonucleotide miR-155 and immunotherapies including pembrolizumab.
